Company news
Newbury Pharmaceuticals AB news in 2025
Newbury Pharmaceuticals AB's news releases, calls and decks from 2025, newest first.
Newbury Pharmaceuticals publishes its annual report for 2024/2025
December 10, 2025
Newbury Pharmaceuticals appoints its founder Karl Karlsson as new CEO
November 11, 2025
Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury
October 24, 2025
Newbury Pharmaceuticals Secures Generic Approval for Ivermectin Newbury
October 23, 2025
Newbury Pharmaceuticals Secures Generic Approval for Melatonin Newbury
August 11, 2025
Newbury Pharmaceuticals carries out a directed share issue of approximately SEK 16 million and extends the existing SEK 15 million loan agreement
April 28, 2025
Newbury Pharmaceuticals Secures Generic Approval for Pazopanib Newbury
April 16, 2025
Newbury Pharmaceuticals expands its portfolio with four new products
March 19, 2025
Newbury Pharmaceuticals Secures Approval for Macitentan film-coated tablets
March 14, 2025
Newbury Pharmaceuticals Secures Generic Approval for Pomalidomide capsules
January 24, 2025
Newbury Pharmaceuticals Secures Generic Approval for Bosutinib tablets
January 22, 2025